GSK (LON:GSK) Sets New 12-Month Low – Should You Sell?

Shares of GSK plc (LON:GSK) hit a new 52-week low during mid-day trading on Wednesday . The company traded as low as GBX 1,368 ($17.81) and last traded at GBX 1,371.89 ($17.86), with a volume of 2147000000 shares. The stock had previously closed at GBX 1,391.50 ($18.11).

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on GSK. JPMorgan Chase & Co. reiterated an “underweight” rating on shares of GSK in a research report on Monday, July 29th. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a GBX 1,850 ($24.08) target price on shares of GSK in a research report on Tuesday, September 3rd. Berenberg Bank reissued a “buy” rating and issued a GBX 1,820 ($23.69) price objective on shares of GSK in a research note on Tuesday, September 10th. Finally, Shore Capital restated a “buy” rating on shares of GSK in a report on Wednesday, August 28th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, GSK has an average rating of “Moderate Buy” and an average price target of GBX 1,842.50 ($23.98).

GSK Trading Down 1.5 %

The firm has a market cap of £55.92 billion, a price-to-earnings ratio of 1,212.83, a PEG ratio of 1.24 and a beta of 0.31. The business has a fifty day moving average of GBX 1,528.84 and a two-hundred day moving average of GBX 1,588.89. The company has a debt-to-equity ratio of 123.04, a quick ratio of 0.73 and a current ratio of 0.82.

GSK Announces Dividend

The company also recently disclosed a dividend, which will be paid on Thursday, January 9th. Stockholders of record on Thursday, November 14th will be paid a GBX 15 ($0.20) dividend. This represents a dividend yield of 1.03%. The ex-dividend date is Thursday, November 14th. GSK’s dividend payout ratio is currently 5,309.73%.

Insider Activity

In other news, insider Jonathan Symonds bought 7,150 shares of the firm’s stock in a transaction dated Wednesday, October 30th. The stock was acquired at an average cost of GBX 1,394 ($18.15) per share, for a total transaction of £99,671 ($129,746.16). In other news, insider Elizabeth (Liz) McKee Anderson bought 446 shares of GSK stock in a transaction on Monday, September 23rd. The shares were bought at an average price of GBX 2,051 ($26.70) per share, with a total value of £9,147.46 ($11,907.65). Also, insider Jonathan Symonds bought 7,150 shares of the firm’s stock in a transaction dated Wednesday, October 30th. The stock was purchased at an average price of GBX 1,394 ($18.15) per share, with a total value of £99,671 ($129,746.16). In the last 90 days, insiders have acquired 7,604 shares of company stock valued at $10,893,886. Company insiders own 1.61% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.